This work develops phase-specific machine learning-based models that support a shift toward feature-resolved, data-driven models in which clinical development success is predicted from the interaction of trial design, sponsor capability, and investigational drug characteristics.
Abstract
Estimating the probability of success (POS) of clinical trials remains a major challenge in drug development. Legacy forecasting approaches in the biopharmaceutical industry rely on historical averages stratified by development phase and therapy area, which obscures the contribution of trial design to clinical outcomes. Here we test the hypothesis that clinical trial design characteristics provide independent predictive signal that can improve estimation of development outcomes. Using a longitudinal dataset of 35,662 clinical trial transitions spanning 27,900 investigational drugs and 5,001 trial sponsors, we developed phase-specific machine learning-based models evaluated under time-aware validation. Models incorporating trial design features produced consistent directional improvements in Phases 1 and 2 and clearer gains in Phase 3 compared with models relying only on drug, indication, and sponsor attributes. Feature importance analysis revealed that trial design-related variables ranked among the strongest predictors when available, whereas exclusion of these variables shifted model reliance toward sponsor experience and investigational drug characteristics. These findings challenge continued industry reliance on aggregate historical benchmarks. They support a shift toward feature-resolved, data-driven models in which clinical development success is predicted from the interaction of trial design, sponsor capability, and investigational drug characteristics. Further, the proposed framework establishes a scalable approach for integrating emerging clinical development data sources that may enable more informed portfolio strategy and trial design decisions.
About 15% of clinical trials terminate prematurely (fail), causing financial losses and delaying treatment development. This study utilized a subset of interventional trial records from the 471,252 studies registered in ClinicalTrials.gov until November 2023 to develop a clinical trial failure risk assessment machine l...
N. Cihoric, Stojan Gavric, F. Dennstädt et al.· Discover Artificial Intellig...· 0 citations
MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success, is developed.
H. H. Caline Koh-Tan, Ivan Meić, Buğra Alptekin Sarı et al.· bioRxiv· 0 citations
An adaptive design is proposed to improve power for detecting a predictive effect when sample sizes are small, and addresses key methodological challenges, including interim decision rules, determining the magnitude and allocation of post‐interim sample size increases, controlling the Type I error rate, and achieving m...
Libby Daniells, Julia Geronimi, Hugo Hadjur et al.· Statistics in Medicine· 0 citations
This review aims to contextualize the bench-to-bedside translational gap, offering an evidence-based roadmap for clinicians, statisticians, and data scientists to safely harness predictive modeling and ensure meaningful improvements in patient outcomes.
Bing-Yi Wang, A. Franciosi, L. O'Neill et al.· Journal of the American Hear...· 0 citations
Around a quarter of drug development now has a Chinese origin, yet China-specific success benchmarks and forecasting tools remain scarce. We analyze all nongeneric drug trials registered on China's national drug clinical trial registry from 2013 to 2025, benchmark phase-transition probabilities of success (PoS)-where s...
Chao-Yi Zhao, Timothy Pang, Andrew W. Lo· Drug Discovery Today· 0 citations
In which situations the ancillary data affect CPM performance, given potential heterogeneity, this study explores in which situations the ancillary data affect CPM performance, given potential heterogeneity.
Haya Elayan, M. Sperrin, G. Martin et al.· Biometrical journal. Biometr...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.